GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Type 2 Diabetes Management
2026 | IAA Journal of Biological Sciences | Pp. 45-54
Type 2 diabetes mellitus (T2DM) affects approximately 537 million adults globally, with projections indicating 783 million cases by 2045, driving substantial cardiovascular and renal morbidity. Monotherapy with glucagon-like peptide-1 receptor agonists (GLP-1...